Clinical Outcomes of Pulmonary Embolism in Mexican Patients With COVID-19.
Luis O Bobadilla-RosadoSantiago Mier Y Teran-EllisGabriel Lopez-PenaJavier E Anaya-AyalaCarlos A HinojosaPublished in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2021)
Coagulation abnormalities have been reported in COVID-19 patients, which may lead to an increased risk of Pulmonary Embolism (PE). We aimed to describe the clinical characteristics and outcomes of COVID-19 patients diagnosed with PE during their hospital stay. We analyzed patients with PE and COVID-19 in a tertiary center in Mexico City from April to October of 2020. A total of 26 (100%) patients were diagnosed with Pulmonary Embolism and COVID-19. We observed that 14 (54%) patients were receiving either prophylactic or full anticoagulation therapy, before PE diagnosis. We found a significant difference in mortality between the group with less than 7 days (83%) and the group with more than 7 days (15%) in Intensive Care Unit (P = .004); as well as a mean of 8 days for the mortality group compared with 20 days of hospitalization in the survivor group (P = .003). In conclusion, there is an urgent need to review antithrombotic therapy in these patients in order to improve clinical outcomes and decrease hospital overload.
Keyphrases
- pulmonary embolism
- end stage renal disease
- sars cov
- intensive care unit
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronavirus disease
- stem cells
- atrial fibrillation
- venous thromboembolism
- bone marrow
- patient reported outcomes
- smoking cessation
- electronic health record
- extracorporeal membrane oxygenation